OBIONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Orchestra BioMed Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$5.65+0.20 (+3.67%)
Close on Oct 19, 2026
- Market cap
- $360.54M
- P/E (TTM)
- –
- Dividend yield
- –
Orchestra BioMed Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue | $504.00K | $585.00K | $611.00K | $621.00K | $665.00K | $646.00K | $633.00K | $631.00K | $595.00K | $632.00K | $654.00K | $652.00K | 1.6% | -24.2% |
| Partnership revenue | – | – | $32.87M | $2.20M | $2.28M | $2.24M | $2.01M | $2.02M | $1.48M | $1.58M | $2.11M | $2.95M | – | – |
By region
From the segment and revenue-disaggregation notes of Orchestra BioMed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.